74 related articles for article (PubMed ID: 17331230)
1. Dispensing patterns of medicines prescribed by Australian dentists from 2006 to 2018 - a pharmacoepidemiological study.
Park JS; Page AT; Kruger E; Tennant M
Int Dent J; 2020 Aug; 71(2):106-12. PubMed ID: 32856305
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Australian Bushfires on Asthma Medicine Prescription Dispensing.
Zhu Z; Naunton M; Mortazavi R; Bushell M
Healthcare (Basel); 2024 Feb; 12(4):. PubMed ID: 38391803
[TBL] [Abstract][Full Text] [Related]
3. The changing face of Australian data reforms: impact on pharmacoepidemiology research.
de Oliveira Costa J; Bruno C; Schaffer AL; Raichand S; Karanges EA; Pearson SA
Int J Popul Data Sci; 2021 Apr; 6(1):1418. PubMed ID: 34007904
[TBL] [Abstract][Full Text] [Related]
4. Fifty years of advancing biologicals and beyond.
Gupta R; Elwyn G; Vyas G; Thorpe R; Baylor N
Biologicals; 2024 Feb; 85():101727. PubMed ID: 37992427
[No Abstract] [Full Text] [Related]
5. Biologicals.
de Carvalho JF; Appenzeller S; Shoenfeld Y
Int J Rheumatol; 2012; 2012():892873. PubMed ID: 22536258
[No Abstract] [Full Text] [Related]
6. Performance-Based Risk-Sharing Arrangements: An Updated International Review.
Carlson JJ; Chen S; Garrison LP
Pharmacoeconomics; 2017 Oct; 35(10):1063-1072. PubMed ID: 28695544
[TBL] [Abstract][Full Text] [Related]
7. Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis.
Sruamsiri R; Wagner AK; Ross-Degnan D; Lu CY; Dhippayom T; Ngorsuraches S; Chaiyakunapruk N
BMJ Open; 2016 Mar; 6(3):e008671. PubMed ID: 26988346
[TBL] [Abstract][Full Text] [Related]
8. Patient access schemes in Asia-pacific markets: current experience and future potential.
Lu CY; Lupton C; Rakowsky S; Babar ZU; Ross-Degnan D; Wagner AK
J Pharm Policy Pract; 2015; 8(1):6. PubMed ID: 25815200
[TBL] [Abstract][Full Text] [Related]
9. Determinants of medication non-adherence in Egyptian patients with systemic lupus erythematosus: Sharkia Governorate.
Abdul-Sattar AB; Abou El Magd SA
Rheumatol Int; 2015 Jun; 35(6):1045-51. PubMed ID: 25424491
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Medication Adherence in Patients with Rheumatoid Arthritis.
Salt E; Frazier SK
Drug Dev Res; 2011 Dec; 72(8):756-763. PubMed ID: 22267889
[TBL] [Abstract][Full Text] [Related]
11. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank.
DeWitt EM; Lin L; Glick HA; Anstrom KJ; Schulman KA; Reed SD
Clin Ther; 2009 Aug; 31(8):1871-80; discussion 1858. PubMed ID: 19808146
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.
Lu CY
Clin Rheumatol; 2009 Apr; 28(4):371-7. PubMed ID: 19190976
[TBL] [Abstract][Full Text] [Related]
13. Access to high cost medicines in Australia: ethical perspectives.
Lu CY; Macneill P; Williams K; Day R
Aust New Zealand Health Policy; 2008 May; 5():4. PubMed ID: 18489760
[TBL] [Abstract][Full Text] [Related]
14. The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.
Lu CY; Williams KM; Day RO
Aust New Zealand Health Policy; 2007 Mar; 4():2. PubMed ID: 17331230
[TBL] [Abstract][Full Text] [Related]
15. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
Lu CY; Williams KM; Day RO
Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
[TBL] [Abstract][Full Text] [Related]
16. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?
Lu CY; Williams KM; Day RO
Intern Med J; 2006 Jan; 36(1):19-27. PubMed ID: 16409309
[TBL] [Abstract][Full Text] [Related]
17. To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?
Gisev N; Pearson SA; Karanges EA; Larance B; Buckley NA; Larney S; Dobbins T; Blanch B; Degenhardt L
Pharmacoepidemiol Drug Saf; 2018 May; 27(5):550-555. PubMed ID: 29047196
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
19. [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies].
Sautner J; Leeb BF
Wien Med Wochenschr; 2003; 153(13-14):304-8. PubMed ID: 12924105
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
